Enfortumab vedotin: Difference between revisions
From IDWiki
Content deleted Content added
Created page with "* Antibody-drug conjugate targeting Nectin-4 that is present on the surface of most urothelial cancer cells * Indicated for urothelial cancer * Common adverse effects include: rashes (about 50%, can be severe), alopecia (in about 50%); abdominal pain, anorexia, constipation, diarrhea, and nausea/vomiting; fatigue; myelosuppression; myalgias; dysgeusia; peripheral neuropathy (in about 50%, can be severe); dry eyes ** Also liver enzyme abnormalities, insomnia, hypergly..." |
(No difference)
|
Latest revision as of 15:32, 2 October 2025
- Antibody-drug conjugate targeting Nectin-4 that is present on the surface of most urothelial cancer cells
- Indicated for urothelial cancer
- Common adverse effects include: rashes (about 50%, can be severe), alopecia (in about 50%); abdominal pain, anorexia, constipation, diarrhea, and nausea/vomiting; fatigue; myelosuppression; myalgias; dysgeusia; peripheral neuropathy (in about 50%, can be severe); dry eyes
- Also liver enzyme abnormalities, insomnia, hyperglycemia
- Rarely SJS/TEN and pneumonitis (median time to onset 3 months)
